Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 9:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 562 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Systemic Lupus Erythematosus Clear all
Withdrawn Phase 4 Interventional

Levothyroxine in Pregnant SLE Patients

NCT01276782
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Levothyroxine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2015 · Synced Oct 14, 2026, 9:55 PM EDT
Terminated Phase 1 Interventional

Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

NCT03656627
View directory record Official record
Conditions
Autoimmune Diseases, Non-small Cell Lung Cancer, Rheumatoid Arthritis, Psoriasis, Giant Cell Arteritis, Polymyalgia Rheumatica, Systemic Lupus Erythematosus, Crohn Disease, Multiple Sclerosis, Ulcerative Colitis
Interventions
Nivolumab
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Chicago, Illinois • Boston, Massachusetts • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 14, 2026, 9:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Role of Antibodies in Cognitive Dysfunction in Patients With Systemic Lupus Erythematosus

NCT00042523
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 14, 2026, 9:55 PM EDT
Active, not recruiting Phase 1 Interventional

A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease

NCT06544330
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis
Interventions
SYNCAR-001, STK-009
Drug
Lead sponsor
Synthekine
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2041
U.S. locations
6
States / cities
Scottsdale, Arizona • Hackensack, New Jersey • Manhasset, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 14, 2026, 9:55 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT05531565
View directory record Official record
Conditions
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Interventions
Litifilimab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
62
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 14, 2026, 9:55 PM EDT
Recruiting Phase 1 Interventional

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

NCT03816345
View directory record Official record
Conditions
Autoimmune Disease, Crohn Disease, Dermatomyositis, Hematopoietic and Lymphoid Cell Neoplasm, Inflammatory Bowel Disease, Malignant Solid Neoplasm, Multiple Sclerosis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis
Interventions
Biospecimen Collection, Cabozantinib, Fluoropyrimidine, Ipilimumab, Nivolumab, Platinum Compound, Platinum Doublet
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
51
States / cities
Birmingham, Alabama • Palo Alto, California • Sacramento, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 14, 2026, 9:55 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Systemic Lupus Erythematosus in Gullah Health

NCT00756769
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Not listed
Lead sponsor
Medical University of South Carolina
Other
Eligibility
2 Years and older
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Phase 2 Interventional Results available

Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus

NCT00076752
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
fludarabine phosphate, cyclophosphamide, Rituxan (rituximab), filgrastim, methylprednisolone, immunologic technique, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, Diphenhydramine, Mesna
Drug · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years to 40 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Phase 2 Interventional

Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)

NCT02633163
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Low Dose Mesenchymal Stem Cells (MSCs), High Dose Mesenchymal Stem Cells (MSCs), Placebo Infusion
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Early Phase 1 Interventional

Preventive IVIG Therapy for Congenital Heart Block

NCT00460928
View directory record Official record
Conditions
Congenital Heart Block, Neonatal Lupus, Autoantibody-associated Heart Block
Interventions
intravenous immune globulin (IVIG)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Livingston, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Not applicable Interventional

Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome

NCT00010400
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome
Interventions
Cyclophosphamide, filgrastim
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Not applicable Interventional

Lupus Walking Intervention to Address Fatigue/Quality of Life

NCT07481214
View directory record Official record
Conditions
System Lupus Erythematosus(SLE)
Interventions
guided increases in daily walking
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Phase 2 Interventional

Serologically Active, Clinically Stable Systemic Lupus Erythematosus

NCT00000421
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Prednisone, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
13 Years to 65 Years · Female only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
3
States / cities
New Hyde Park, New York • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 14, 2026, 9:55 PM EDT
Withdrawn Phase 3 Interventional

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)

NCT06456567
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Telitacicept, Placebo
Biological · Drug
Lead sponsor
Vor Biopharma
Industry
Eligibility
12 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Hemet, California • Menifee, California • Rockford, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Phase 3 Interventional Results available

A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus

NCT02504645
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
IPP-201101, Placebo, Standard of Care
Drug · Other
Lead sponsor
ImmuPharma
Industry
Eligibility
18 Years to 70 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
9
States / cities
Los Angeles, California • San Leandro, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus

NCT02194400
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
RSLV-132
Biological
Lead sponsor
Resolve Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Clearwater, Florida • Grand Rapids, Michigan • Duncansville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 14, 2026, 9:55 PM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

NCT05648500
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Cenerimod, Placebo
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
Huntington Park, California • Aurora, Colorado • Clearwater, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 14, 2026, 9:55 PM EDT
Recruiting No phase listed Observational

CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry

NCT06804057
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Blood Collection
Other
Lead sponsor
CorEvitas
Network
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2099
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 14, 2026, 9:55 PM EDT
Recruiting Phase 1 Interventional

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

NCT07201558
View directory record Official record
Conditions
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Interventions
Surovatamig
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Birmingham, Alabama • Fullerton, California • Plantation, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 14, 2026, 9:55 PM EDT
Completed No phase listed Observational

Pilot Study to Assess Flares Following Inactivated Influenza Vaccine in Children With Systemic Lupus Erythematosus (SLE)

NCT02006784
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
8 Years to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Oct 14, 2026, 9:55 PM EDT
Terminated Phase 1 Interventional

Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases

NCT00849745
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Systemic Sclerosis
Interventions
Nonmyeloablative allogeneic stem cell transplant
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 69 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Oct 14, 2026, 9:55 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis

NCT00573157
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Atacicept, Mycophenolate mofetil, Placebo, Corticosteroids
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
16 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
12
States / cities
New Orleans, Louisiana • Shreveport, Louisiana • Detroit, Michigan + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 14, 2026, 9:55 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Comparative Autoantibody and Immunologic Cell Marker Study

NCT02422875
View directory record Official record
Conditions
Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 9:55 PM EDT
Active, not recruiting Not applicable Interventional

Engagement in CHildhood-Onset Systemic Lupus

NCT05693571
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Depression
Interventions
Valera Smart Phone Application and Care Manager Dashboard
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
15 Years to 25 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 14, 2026, 9:55 PM EDT